about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
Company profile
Ticker
KOD
Exchange
Website
CEO
Victor Perlroth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Oligasis, LLC
SEC CIK
Corporate docs
IRS number
270476525
KOD stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
15 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
14 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 252.10 mm | 252.10 mm | 252.10 mm | 252.10 mm | 252.10 mm | 252.10 mm |
Cash burn (monthly) | 13.24 mm | 5.90 mm | 15.35 mm | 20.73 mm | 13.20 mm | 12.21 mm |
Cash used (since last report) | 21.99 mm | 9.80 mm | 25.50 mm | 34.43 mm | 21.92 mm | 20.28 mm |
Cash remaining | 230.11 mm | 242.30 mm | 226.61 mm | 217.68 mm | 230.18 mm | 231.82 mm |
Runway (months of cash) | 17.4 | 41.0 | 14.8 | 10.5 | 17.4 | 19.0 |
Institutional ownership, Q4 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 97 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 92.00 k |
Total shares | 17.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
SG Americas Securities | 17.69 k | $54.00 k |
Thrivent Trust Co of Tennessee | 69.00 | $0.00 |
GPS Wealth Strategies | 6.00 | $18.00 k |
Global Retirement Partners | 6.00 | $20.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun 23 | Bancroft Charles A | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Bassil I Dahiyat | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Levy Richard S | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Profusek Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Yang Taiyin | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
News
Kodiak Sciences Q1 2024 GAAP EPS $(0.82) Beats $(1.07) Estimate
15 May 24
Reported Earlier, Kodiak Sciences Announced Treatment Of First Patients In Phase 3 GLOW2 Study Of Tarcocimab Tedromer In Diabetic Retinopathy
14 May 24
Kodiak Sciences Data At ARVO 2024 Highlight Depth Of Early And Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built On Kodiak's Antibody Biopolymer Conjugate Platform
2 May 24
UBS Maintains Neutral on Kodiak Sciences, Raises Price Target to $5
4 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 Apr 24
Press releases
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
15 May 24
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
13 May 24
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
2 May 24
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
26 Mar 24